



Effects of N-Trans Caffeoyltyramine and N-Trans Feruloyltyramine supplementation in individuals with diarrhea predominant-irritable bowel syndrome: Randomized, double-blind, placebo-controlled trial

Luma Melo¹, Douglas Bolster¹, Swati Kalgaonkar^{2*}, Lee Chae², Sam Treadway³, Sowmya Chinta³, Sarah Bloor³, Haddasah Black³, Christopher R. D'Adamo⁴, Elizabeth Coy⁵, and Anthony Hobson³

¹ Formerly Brightseed, South San Francisco, CA, USA; ² Brightseed, South San Francisco, CA, USA; ³ The Functional Gut Clinic, Manchester, UK; ⁴ University of Maryland School of Medicine, Baltimore, MD, USA; ⁵ The Quadram Institute, Norwich, UK

*Correspondence: Swati Kalgaonkar, Brightseed, 201 Haskins Way, South San Francisco, CA 94080, USA.

Submission Date: May 28th, 2025; **Acceptance Date:** June 6th, 2025; **Publication Date:** June 10th, 2025

Please cite this article as: Melo L., Bolster D., Kalgaonkar S., Chae L., Treadway S., Chinta S., Bloor S., Black H., D'Adamo C. R., Coy E., Hobson A. Effects of N-Trans Caffeoyltyramine and N-Trans Feruloyltyramine supplementation in individuals with diarrhea-predominant irritable bowel syndrome: Randomized, double-blind, placebo-controlled trial. *Bioactive Compounds in Health and Disease* 2025; 8(6): 204 - 217. DOI: <https://doi.org/10.31989/bchd.8i6.1655>

ABSTRACT

Objective: This clinical trial investigated the effects of 3-week ingestion of a proprietary gut health supplement containing the bioactives N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), on intestinal barrier function and on severity of GI symptoms in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D).


Methods: Participants included 29 males and females who met the ROME IV criteria for IBS-D, having lipopolysaccharide (LPS) levels >0.21 ng/ml, and experiencing symptoms related to IBS-D. A randomized, double-blind, placebo-controlled, parallel design was used with a 3-week supplementation period with a dietary supplement providing 120mg of NCT and NFT. The primary outcome measure was Lactulose/Mannitol (L/M) ratio, a measure of intestinal permeability. Secondary endpoints included changes in other biomarkers of intestinal permeability (serum LPS, LBP, sCD14, Zonulin, LCN2) and subjective changes in stool frequency and consistency using the Bristol Stool Chart and bloating and abdominal pain using the IBS Symptom Severity Scale (IBS-SSS).

Results: The NCT/NFT supplementation group showed significant improvements in L/M ratio ($p=0.048$), lipopolysaccharide-binding protein (LBP) levels ($p=0.018$), and the IBS-SSS abdominal distention scores ($p=0.044$) compared to the placebo group, demonstrating improvement in gut barrier integrity and GI comfort. No between-group differences were found for other endpoints. No adverse events were reported, and study compliance was high.

Conclusions: NCT/NFT intake for 3 weeks led to a significant improvement in L/M ratio, LBP, and IBS-SSS abdominal distention scores, and a trend for a decrease in abdominal pain scores, thereby demonstrating marked improvement in both objective and subjective outcomes supporting gut barrier function. This proprietary gut health supplement shows promise for restoring a healthy gut barrier.

Novelty of the Study: This study is among the first randomized, double-blind, placebo-controlled clinical trials to evaluate the effects of N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) supplementation on gut barrier function in individuals with gut barrier compromise, as in the case of IBS-D. While prior research has focused on symptom management in cases of high gut permeability, this study uniquely integrates both objective (e.g., L/M ratio, LBP) and subjective (e.g., IBS-SSS scores) endpoints, providing a comprehensive assessment of gut integrity restoration through novel bioactive compounds. The findings introduce a new direction for bioactive supplementation targeting gut barrier dysfunction.

Keywords: irritable bowel syndrome, dietary supplements, N-trans caffeoyltyramine, N-trans feruloyltyramine, gut barrier function, intestinal permeability



INTRODUCTION

A healthy, functional gut barrier is a hallmark of good gut health. The gut barrier is a collection of layers, including intestinal mucus and epithelial cells, that separates the lumen from the rest of the intestinal tissues and broader circulatory system [1]. It is the barrier between the inner workings of the human body and the environment. When functioning optimally, the gut barrier only allows transport of desirable nutrients and compounds into the cells or adjacent paracellular space. With impaired function, undesirable elements can enter the intercellular space to cause intestinal dysbiosis and move into the circulatory systems to cause systemic effects. A weakened gut barrier increases susceptibility to a range of gut-mediated effects. This can include low-grade inflammation due to translocation of bacteria-derived lipopolysaccharides from the lumen to the interstitial space via “leaky” tight junctions [2]. A weakened gut barrier is common in conditions like irritable bowel syndrome (IBS).

In the United States (US), conditions related to irritable bowel are highly prevalent, reportedly affecting up to 15% of the population [3]. IBS is divided into four subtypes: IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (IBS with mixed bowel habits), and unclassified. IBS-D is the most common of these, affecting almost half of those with IBS [4]. Persistent GI-related symptoms in IBS-D, such as frequent diarrhea and abdominal discomfort, disrupt daily activities and negatively affect quality of life [5- 6]. Recent treatments focus on symptom management using dietary modifications, probiotics, pharmacological interventions, and psychological therapies; however, many people report only partial relief [7]. Emerging evidence supports the role of nutrition-based strategies in IBS-D management, particularly supplements and dietary interventions that target intestinal barrier function [8].

Bioactive compounds have been shown to impart several human health benefits and are rising considerably in popularity among consumers [9]. Bioactives, components of food that provide benefits beyond what is required for basic physiological function [10], are now being explored for their potential role in improved gut barrier function [11]. N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) are naturally occurring bioactive compounds with potential therapeutic benefits related to gut disorders. These compounds have been associated with anti-inflammatory and gut-barrier-enhancing properties in preclinical models, including improvements in tight junction integrity and reductions in intestinal permeability [12, 13]. Given the growing evidence linking gut permeability with IBS-D pathophysiology, investigating the effects of NCT and NFT in this population is of significant interest. Further, the overt nature of IBS-D symptomology allows for comprehensive evaluation of both objective and subjective improvements in gut barrier function.

Therefore, this study aimed to investigate the effects of a proprietary dietary supplement containing bioactive compounds NCT and NFT on intestinal barrier function in individuals with IBS-D. The findings will contribute to existing evidence in the field and help support the design of larger-scale clinical trials exploring dietary interventions that support gut barrier health.

MATERIALS AND METHODS

Study population: Study participants included male and female adults ages 18 to 70 years, with a body mass index (BMI) of 18.5 – 39.9kg/m², who met the ROME IV criteria for IBS-D [14] confirmed by bowel diary, and IBS-SSS score above 175. Participants presented LPS levels greater than 0.21 ng/mL, indicating increased intestinal permeability [15, 16]. Participants were excluded if they had a history of inflammatory bowel disease, recent antibiotic use (within the prior 30 days), chronic NSAID

(nonsteroidal anti-inflammatory drugs) use, major dietary changes, or significant comorbidities that could affect gut function. Participants were screened through medical history obtained from their general practitioner, symptom assessment, and baseline biomarker evaluation. After screening 90 potential participants for eligibility, 32 were enrolled and 29 completed the study

protocol (Figure 1). Informed consent was obtained from all persons involved. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Chelsea Research Ethics Committee, London, UK (Approval Number: 344580). This trial was registered on ClinicalTrials.gov (ID: NCT06543498).




Figure 1. Participant flow diagram.

Study Design: This study utilized a double-blinded, randomized, placebo-controlled parallel design with a 3-week intervention period. The active intervention and placebo were identical in appearance. This study included 3 visits to the Functional Gut Clinic (FGC) of either London or Manchester in the United Kingdom (Figure 2). The purpose of this study was to investigate

the effects of a proprietary NCT/NFT supplement (Brightseed® Bio Gut Core) on markers of gut barrier function, including Lactulose/Mannitol ratio, Lipopolysaccharide (LPS), Lipopolysaccharide Binding Protein (LBP), sCD14, Zonulin, and LCN2, and the severity of symptoms related to IBS-D. Data collection was completed between August 2024 and January 2025.




Figure 2. Intervention Period: Baseline and End-of-Study Visits.

L/M: Lactulose/Mannitol; IBS-SSS: Irritable Bowel Syndrome Symptom Severity Scale

Participants were recruited through advertisements on social media, newspapers, and the FGC website, as well as through direct contact with those who had previously consented to being approached for research opportunities. Those who were interested completed a virtual informed consent document and received a screening phone call to verify basic demographic details, medical history, and current medication list to confirm suitability for the study. After suitability was confirmed, a screening visit (Visit 1) was scheduled.

During Visit 1, in-person informed consent was obtained, and a comprehensive medical history and medication intake were recorded. Participants completed the ROME IV questionnaire and completed a 14-day bowel habit diary using the Bristol Stool Chart to confirm IBS-D status. A blood sample was collected to assess gut barrier dysfunction, with eligibility confirmed by LPS levels >0.21 ng/ml. Females with childbearing potential underwent a urine pregnancy test to confirm non-pregnancy. Upon meeting all eligibility criteria, participants received instructions to follow a specific diet, avoiding foods with lactulose and mannitol one day before Visit 2, and were provided with a 3-day food

record to complete on three consecutive days prior to Visit 2. Also at this visit, participants were randomized to their allocated treatment group using a pre-determined block randomization code. Both the participants and the research team were blinded to treatment allocation.

During Visit 2, study participants arrived at the FGC in an overnight fasted state, returned the 3-day food record, and completed questionnaires including the IBS-SSS. A blood sample was collected. Participants then ingested a lactulose/mannitol test solution prepared with two sugar probes (5 g mannitol and 10 g lactulose) in ~200 mL of water. Following solution ingestion, participants completed an in-clinic 8 h urine collection. Water consumption was permitted ad libitum during the collection period. After samples were collected, participants received a bottle with a 3-week supply of NCT/NFT dietary supplement capsules with instructions to consume 1 capsule daily. Study participants were also given another bowel diary with Bristol Stool Chart and a 3-day food record to be completed over the next 3-week treatment period prior to Visit 3. Urine samples were aliquoted and stored in a -80°C freezer until analysis.

During Visit 3, participants returned completed bowel habit diary and 3-day food record. Supplement bottles were collected, and remaining capsules were counted to verify compliance. Participants who met compliance requirements repeated all procedures performed during Visit 2.

Assessment of Intestinal Permeability

Lactulose/Mannitol Ratio: The Lactulose/Mannitol ratio test was used to assess gut permeability. This is the gold standard for such assessment [17]. Participants were instructed to follow a specific diet on the day before the study to improve the accuracy of the test by reducing background mannitol occurring in foods. They fasted for 12 hours prior to the study. Participants provided a fasted urine void before ingesting a dual sugar probe: Lactulose (a synthetic non-absorbable disaccharide) and Mannitol (a naturally occurring poorly absorbed monosaccharide). Total urine was then collected over 0-8 h period. The concentration of both sugar molecules was detected with high-performance liquid chromatography (HPLC) using a resin-based cation exchange column with a refractive index detector for recovery. The ratio of lactulose/mannitol excretion determines gut barrier dysfunction.

Gut Barrier Biomarkers: Serum biomarkers were also used to evaluate the strength of the gut barrier. Blood samples were collected at clinic visits 1, 2 & 3, by a phlebotomy certified member of the research team. Samples were centrifuged to aliquot viable serum and plasma which were frozen and stored at -80 °C. LPS was detected using the Limulus amoebocyte lysate quantitative end-point assay. The values for serum LBP,

sCD14, Zonulin, and LCN2 were obtained using quantitative enzyme-linked immunosorbent assay (ELISA). LPS was also used during the screening phase as part of the eligibility assessment to verify evidence of increased intestinal permeability prior to randomization.

Assessment of GI-Symptoms

ROME IV: The ROME IV criteria for IBS, a validated questionnaire used to identify functional GI disorders, were used for this purpose. The 89-point questionnaire contains questions relating to the esophagus, stomach, and abdomen and can be used as a diagnostic tool, particularly in the research setting, to classify participants with one (or more) of the 33 recognized functional GI disorders in adults. For the purposes of the study, only the IBS-specific questions (#40-67) were used to reduce participant burden.

IBS-SSS: The IBS-Symptom Severity Score (IBS-SSS), a validated questionnaire used to determine the severity of abdominal and bowel symptoms, was used for this purpose. The questionnaire is comprised of 7 questions, 2 visual analogue and 5 numerical, which are scored from 0 to 10. The total of the 5 numerical questions was calculated and multiplied by 10 to determine symptom severity. 75–174 indicates mild disease, 175–300 moderate, and over 300 severe diseases. The IBS-SSS was administered on each of the 3 scheduled study visits. Use of the IBS-SSS in this study was licensed by the Rome Foundation.

Bowel Habit Diary and Bristol Stool Chart: Participants were asked to complete a bowel habit diary throughout the study. The first 14 days were used to assess eligibility based on IBS-D symptomatology. Completion of the diary

through randomized treatment (21 days) was used to determine changes in bowel habit over time. The diary collected information on symptoms associated with bowel habit and the Bristol Stool Score grading of each bowel movement. The Bristol Stool Chart is a validated diagram, encompassing images and descriptions of 7 distinct stool types for participants to describe their bowel movements. The Bristol Stool Chart was licensed by the Rome Foundation for use in this study.

Compliance

Food Records: Participants completed three-day food records to verify compliance with the protocol (including pre-visit dietary restrictions) and confirm maintenance of habitual diet throughout the intervention. Intake was recorded on three consecutive days before the baseline visit and the end of treatment visit. Participants were asked to record all food and drink consumed, with quantities/descriptions in as much detail as possible, including brand names etc. Over the counter or prescribed pre- or probiotics were not permitted.

Safety Blood Assessments: Hematology and clinical chemistry analyses were performed at local laboratories according to their protocols. The investigator was supplied with values to evaluate clinical significance and pathological changes.

Statistical Analysis: A pragmatic sample size of 28 participants (~14 per group) was needed. The sample size calculation is for the L/M ratio, primary endpoint, to detect a minimal clinically significant difference of 0.02, with a standard deviation of 0.025, at 80% power and an alpha level of 0.05 (two-tailed). Data are expressed as

mean \pm standard deviation and analyzed using SPSS (IBM SPSS Statistics, Version 27.0, IBM Corp, Armonk, NY, USA) or JASP 0.19.3. Normality was assessed using the Shapiro-Wilk test. Between-group differences were evaluated using independent t-tests for normally distributed variables and Mann-Whitney U tests for non-normally distributed variables. Within-group differences were evaluated using paired t-tests for normally distributed variables and Wilcoxon signed-rank tests for non-normally distributed variables. For the L/M data, a spaghetti plot was used to visually identify outliers, which were subsequently removed prior to analysis of that endpoint (one outlier removed per treatment group). A p-value of <0.05 was considered statistically significant. Effect sizes were calculated to determine the magnitude of observed differences.

RESULTS

Participant Characteristics at Baseline: A total of 29 participants ($n=11$ males, $n=18$ females) completed all study procedures. NCT/NFT ($n=15$) and placebo ($n=14$) groups did not differ in age, BMI, and sex ($p>0.05$).

Lactulose/Mannitol Ratio: The primary outcome measure was change in intestinal permeability as measured by the L/M ratio, which was evaluated within and between groups.

Within Group Analysis: NCT/NFT: Mean decrease in overall L/M ratio (0- 8 hr) was from 0.074 at baseline, to 0.033 at end of study in the NCT/NFT group. The difference in L/M ratio from baseline to end of study in the NCT/NFT group was statistically significant ($p=0.044$).

Within Group Analysis: Placebo: Mean decrease in overall L/M ratio (0-8 hr) was from 0.067 (median 0.041) at baseline, to 0.041 (median 0.032) at end of study in the placebo group. The difference in L/M ratio from baseline to end of study in the placebo group was not statistically significant ($p=0.295$).

Between Group Analysis: NCT/NFT vs Placebo: Throughout the 3-week trial, L/M ratio was significantly decreased following treatment with NCT/NFT compared to placebo (mean change: -0.06 vs. -0.01; $p=0.048$; Figure 3) after accounting for outliers, one from each group based on spaghetti plot analysis.




Figure 3. Change in L/M Ratio (0-8 h) by Treatment Group

Data are expressed as means \pm standard deviation; Asterisk (*) indicates p -value <0.05

Serum Lipopolysaccharide Binding Protein (LBP): Serum LBP, a surrogate marker of endotoxemia due to gut barrier dysfunction, showed a statistically significant

improvement with the treatment of NCT/NFT compared to placebo (mean change: -0.43 vs. 0.62; $p=0.018$; Figure 4).




Figure 4. Change in Serum LBP by Treatment Group

Data are expressed as means \pm standard deviation; Asterisk (*) indicates p -value <0.05

Other Gut Barrier Biomarkers: Changes in other gut barrier biomarkers (serum LPS, sCD14, Zonulin, LCN2) were not statistically significant when comparing between-group effects ($p>0.05$).

IBS-Symptom Severity Score (IBS-SSS): The IBS-symptom severity score measured abdominal distension and pain, dissatisfaction with bowel habits, and interference with

quality of life. The NCT/NFT group described greater relief for all symptoms, with the exclusion of bowel function dissatisfaction, compared to the placebo group. Notably, the severity of abdominal distension was significantly reduced in the NCT/NFT group compared to the placebo group (mean change: -34.0 vs. -12.9; $p=0.044$; Figure 5) following the 3-week treatment period.




Figure 5. Change in Severity of Abdominal Distension by Treatment Group

Data are expressed as means \pm standard deviation; Asterisk (*) indicates p -value <0.05

Bristol Stool Score (BSS): GI-related symptomology was generally improved with NCT/NFT treatment. From week 1 to week 3 of the intervention, the mean number of days with a diarrhea-type bowel movement decreased by 0.12 in the NCT/NFT group compared to an increase of 0.01 in the placebo group ($p=0.17$). A similar trend was seen for the number of daily bowel movements, where the mean frequency

decreased by 0.26 with NCT/NFT treatment compared to a mean increase of 0.10 with placebo ($p=0.121$). A strong trend was observed for reductions in abdominal pain during the 3-week treatment period (NCT/NFT: -1.33 vs placebo: -0.16; $p=0.11$; Figure 6). Bloating also reduced during treatment (NCT/NFT: -1.13 vs placebo: -0.42), although not significantly ($p=0.321$).




Figure 6. Change in Severity of Abdominal Pain by Treatment Group

Data are expressed as means \pm standard deviation

Exploratory Endpoints: Correlations: Select biomarkers of gut barrier strength were correlated with intestinal permeability and GI-related symptom severity measures. There was a positive correlation between changes in LBP and L/M ratio ($r=0.399$) for both groups combined ($p<0.05$). Further, this correlation was stronger in the NCT/NFT group ($r=0.489$). Additionally, an inverse correlation was observed between changes in IBS-SSS and LPS levels ($r=-0.524$), which agrees with existing findings that LPS levels may be associated with symptom severity in IBS-D [18].

Dietary Compliance: Participants completed a 3-day food record before and after the intervention period, which confirmed compliance with the protocol and demonstrated similar energy and macronutrient (fat, carbohydrate, protein, and fiber) intake between groups.

Safety and Adverse Events: Clinical chemistry tests were conducted in the NCT/NFT treatment group before and after the intervention. No safety-related events were observed, and all values remained within the normal range. Further, no adverse events related to the study treatment were reported in either study arm.

DISCUSSION

The gut barrier is the partition between the body's internal systems and the external environment and is fundamental to gut and overall health. A weakened gut barrier increases susceptibility to gut-related health issues, including gut inflammation. A dysfunctional gut barrier also has adverse physiological implications, such as impaired nutrient absorption and endotoxemia [16, 19]. Additionally, resulting symptoms such as frequent diarrhea, abdominal pain, and bloating impede activities of daily living and negatively impact overall quality of life [6].

Conditions characterized by chronic, low-grade inflammation, such as obesity, are also often linked to an

impaired intestinal barrier [20]. Recent evidence supports the theory that excess weight contributes to gut dysbiosis and is associated with symptoms of IBS [20]. Indeed, the prevalence of IBS in those with obesity is higher than in the general population, with over 30% of obese persons being affected [20]. Considering that almost three-quarters (73.6%) of the adult population in the US is either overweight or obese [21], it is likely that a substantial number of people are at increased risk for having a compromised gut barrier and/or associated symptomology.

In addition, some medications can also adversely impact GI symptoms and the gut barrier. For instance, obesity treatments now include pharmacotherapy, namely, glucagon-like peptide-1 (GLP-1) receptor agonists. These medications have demonstrated substantial effectiveness and are quickly gaining popularity [22]. One of the mechanisms by which GLP-1 receptor agonists work is by delaying gastric emptying [23]. This slowed motility may mimic symptoms of IBS, like abdominal distension and pain [24], and is also associated with increased frequency of diarrhea [25, 26].

Athletes or those participating in endurance sports are also known to have a high incidence of GI-related issues [27]. Data shows that strenuous exercise may induce intestinal hyperpermeability [28]. Indeed, nutritional interventions targeting the gut barrier showed promising results [29], suggesting that supplement intake aimed at improving gut barrier integrity has novel applications and can be extrapolated to this group, in addition to those suffering from inflammatory bowel conditions.

Many lifestyle-related and pharmacological treatments rightly focus on symptom management to provide acute relief [7]. One example is a synthetic antimicrobial drug, a non-systemic, broad-spectrum antibiotic targeting the gut/intestinal microbiota [30]. In phase 3 (with double-blind, placebo-controlled trials),

participants who had IBS without constipation were treated with either this antibiotic (550 mg, 3x/day) or placebo for 2 weeks. Indeed, treatment with the antibiotic provided significant relief of IBS symptoms, bloating, abdominal pain, and loose stools [30], suggesting its usefulness in the short term. As an antibiotic, however, its utility is limited in terms of ongoing support. The long-term effects of these types of drugs have not been studied, and they are not indicated for repeated treatments [31-32]. Further, high costs associated with drugs may also be prohibitive to consumers [31-32]. On the other hand, long-term management of IBS and related GI symptoms often involves lifestyle modification, including dietary intervention and supplement intake.

Bioactive compounds, health-benefiting compounds naturally occurring in plants, are becoming increasingly recognized for their biological properties and potential human health benefits [33]. NCT and NFT show particular promise in alleviating GI symptoms through their anti-inflammatory and gut microbiota-modulating properties [12-13]. These compounds act as agonists to hepatocyte nuclear factor 4 alpha (HNF4 α), a nuclear transcription factor influencing intestinal permeability and gut barrier [34]. In vitro, administration of NCT and NFT yielded a physiologically relevant rescue of inflammation-induced impairments in gut barrier function by reversing increased intestinal permeability and decreased transepithelial electrical resistance [13]. In vivo evidence demonstrated the reversal of increased intestinal permeability in a diet-induced obesity mouse model with genetic deletion of HNF4 α that predisposed the animals to IBD [12]. Treatment with NCT mitigated the deleterious effects of a high-fat diet on HNF4 α expression and the genes critical to Paneth cell function, thereby improving intestinal barrier integrity [12]. These preclinical data suggest a crucial role for NCT and NFT in promoting gut barrier function.

The current clinical study was conducted to validate further the efficacy of Brightseed® Bio Gut Core, a proprietary NCT- and NFT-based dietary supplement, on intestinal barrier function and severity of symptoms in individuals with IBS-D. Due to the overt nature of their symptoms, the IBS-D population is an ideal model for assessing gut barrier function and related GI symptoms. Twenty-nine participants completed the present trial and were randomized to either 120 mg/day of NCT/NFT or placebo for 3 weeks. Intestinal permeability, as assessed by the L/M ratio, was significantly decreased in the NCT/NFT group compared to the placebo group ($p < 0.05$). Supplementation with NCT/NFT also significantly decreased LBP, a surrogate marker of endotoxemia due to gut barrier dysfunction, and reduced the severity of abdominal distension as assessed by IBS-SSS ($p < 0.05$). Further, trends in improvement were reported for subjective symptoms of bloating, abdominal pain, and impact on quality of life. The product appeared safe, and no adverse events related to supplementation with NCT/NFT were reported.

While this study's findings are encouraging, several limitations are worthy of consideration. First, the study sample is relatively small, and larger studies would be helpful to replicate these findings. As a novel bioactive compound, the biological processes associated with the physiological improvements seen with NCT and NFT intake can be explored further. To examine potential mechanisms of action, multiple endpoints representing distinct biological pathways were evaluated, with the understanding that not all would necessarily yield positive findings. In this regard, the lack of statistical significance for specific outcomes (serum LPS, sCD14, Zonulin, and LCN2) was expected, providing deeper insight into the underlying mechanisms driving physiological response. Although some of the subjective endpoints (e.g., abdominal pain) did not reach statistical significance, they demonstrated a positive trend in that direction, emphasizing the potential of NCT and NFT in strengthening the gut barrier and providing GI-symptom

relief. The current study showed a placebo response rate of 57% for the IBS-SSS, which is typical of trials in IBS and other disorders involving gut-brain interactions [35]. Although the current study showcased robust results for several parameters, including the primary endpoint of lactulose/mannitol ratio, conducting the study in a larger study population may help reach statistical significance for these endpoints.

In conclusion, supplementation with Brightseed® Bio Gut Core (containing 120 mg/day proprietary NCT/NFT blend) for 3 weeks significantly improved physiologically relevant measures of gut barrier integrity and subjective measures of symptom-induced GI discomfort/pain. These results emphasize the restorative potential of NCT and NFT to provide gut health barrier support and symptom relief.

Scientific Innovation: The trial utilized a rigorous design to evaluate a proprietary supplement containing NCT and NFT, targeting intestinal permeability—an emerging biomarker of gut health. The significant improvements in Lactulose/Mannitol ratio and LBP levels represent clinically meaningful outcomes rarely observed in short-term dietary interventions. Furthermore, the study explored multiple biomarkers across immune and epithelial pathways (e.g., LPS, Zonulin, sCD14, LCN2), offering a multidimensional view of the bioactives' potential mechanisms. These insights help establish NCT/NFT as promising candidates for functional food formulation and clinical nutrition strategies.

Practical Implications

Supplementation with NCT/NFT for just three weeks demonstrated marked improvement in gut barrier integrity and gastrointestinal symptoms in subjects with gut barrier compromise. Given the high placebo response rate typical of trials in subjects with compromised gut barrier, the statistically significant outcomes achieved here highlight the real-world applicability of this intervention. The proprietary formulation shows potential as a dietary supplement for managing gut

permeability issues and offers a non-pharmacological approach for individuals seeking relief from high gut permeability-related discomfort. These findings support its further development for commercial and clinical use in gut health support.

Author Contributions: Conceptualization and methodology: LM, DB, SK, LC, ST, SC; Study coordination and execution: ST, SB, EC; Sample analysis: SC, HB; Study conduct oversight: AH, CD; Manuscript review and editing: SK. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by *Brightseed*®.

Data Availability Statement: The authors will make the raw data supporting this article's conclusions available upon request.

Acknowledgements: The authors would like to acknowledge Michelle Zuelch, PhD, MS RD, and Barkha Gupta, PhD, for their help with manuscript preparation.

Conflicts of Interest: SK and LC are currently employed by *Brightseed*®. Study sponsors had no role in the execution of the study or in the analysis of data.

References

1. Neurath M.F., Artis D., Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. *Lancet Gastroenterol Hepatol.* 2025;10(6):573-592.
DOI: [https://doi.org/10.1016/S2468-1253\(24\)00390-X](https://doi.org/10.1016/S2468-1253(24)00390-X)
2. Mohr A.E., Crawford M., Jasbi P., Fessler S., Sweazea K.L. Lipopolysaccharide and the gut microbiota: considering structural variation. *FEBS Lett.* 2022;596(7):849-875.
DOI: <https://doi.org/10.1002/1873-3468.14328>
3. Irritable Bowel Syndrome (IBS) [<https://gi.org/topics/irritable-bowel-syndrome/>]. Retrieved June 3, 2025.
4. Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L. Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms. *Nutrients.* 2021;13(5):1506.
DOI: <https://doi.org/10.3390/nu13051506>

5. Black C.J., Drossman D.A., Talley N.J., Ruddy J., Ford A.C. Functional gastrointestinal disorders: advances in understanding and management. *The Lancet*. 2020;396(10263):1664-1674.
DOI: [https://doi.org/10.1016/S0140-6736\(20\)32115-2](https://doi.org/10.1016/S0140-6736(20)32115-2)
6. Buono J.L., Carson R.T., Flores N.M. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. *Health Qual Life Outcomes*. 2017;15(1):35.
DOI: <https://doi.org/10.1186/s12955-017-0611-2>
7. Black C.J., Ford A.C. Best management of irritable bowel syndrome. *Frontline Gastroenterol*. 2021;12(4):303-315.
DOI: <https://doi.org/10.1136/flgastro-2019-101298>
8. Shaikh S.D., Sun N., Canakis A., Park W.Y., Weber H.C. Irritable bowel syndrome and the gut microbiome: a comprehensive review. *J Clin Med*. 2023;12(7):2558.
DOI: <https://doi.org/10.3390/jcm12072558>
9. Chen S., Martirosyan D. Marketing strategies for functional food products. *Funct Foods Health Dis*. 2021;11(8):335.
DOI: <https://doi.org/10.31989/ffhd.v11i8.817>
10. Martirosyan D., Stratton S. Quantum and tempus theories of function food science in practice. *Funct Food Sci*. 2023;3(5):55. DOI: <https://doi.org/10.31989/ffs.v3i5.1122>
11. Santonicola A., Molinari R., Piccinocchi G., Salvetti A., Natale F., Cimmino G. Role of a novel nutraceutical composition for irritable bowel syndrome management: symptoms relief and unexpected triglycerides-lowering effect. *Funct Foods Health Dis*. 2023;13(2):82.
DOI: <https://doi.org/10.31989/ffhd.v13i2.1068>
12. Lee S.H., Veeriah V., Levine F. A potent HNF4 α agonist reveals that HNF4 α controls genes important in inflammatory bowel disease and paneth cells. *Dudeja P*, ed. *PLOS ONE*. 2022;17(4):e0266066.
DOI: <https://doi.org/10.1371/journal.pone.0266066>
13. Bolster D., Chae L., Van Klinken J.W., Kalgaonkar S. Impact of selected novel plant bioactives on improvement of impaired gut barrier function using human primary cell intestinal epithelium. *J Food Bioact*. Published online December 2022:11-16. DOI: <https://doi.org/10.31665/JFB.2022.18324>
14. Khasawneh M., Craig O.F., Gracie D.J., Black C.J., Ford A.C. A diagnosis of irritable bowel syndrome using Rome IV criteria and limited investigations is durable in secondary care. *Clin Gastroenterol Hepatol*. 2023;21(13):3397-3404.e1.
DOI: <https://doi.org/10.1016/j.cgh.2023.05.022>
15. Nighot M., Rawat M., Al-Sadi R., Castillo E.F., Nighot P., Ma T.Y. Lipopolysaccharide-induced increase in intestinal permeability is mediated by TAK-1 activation of IKK and MLCK/MYLK gene. *Am J Pathol*. 2019;189(4):797-812.
DOI: <https://doi.org/10.1016/j.ajpath.2018.12.016>
16. Di Vincenzo F., Del Gaudio A., Petito V., Lopetuso L.R., Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. *Intern Emerg Med*. 2024;19(2):275-293.
DOI: <https://doi.org/10.1007/s11739-023-03374-w>
17. Sequeira I.R., Kruger M.C., Hurst R.D., Lentle R.G. A simple, robust, and convenient HPLC Assay for urinary lactulose and mannitol in the dual sugar absorption test. *Molecules*. 2022;27(9):2677.
DOI: <https://doi.org/10.3390/molecules27092677>
18. Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F. Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-IBS: an update. *Rizzo R*, ed. *Dis Markers*. 2020; 2020:1-12.
DOI: <https://doi.org/10.1155/2020/2886268>
19. Ford C.K. Nutrition considerations in patients with functional diarrhea. *Curr Gastroenterol Rep*. 2023;25(9):198-203.
DOI: <https://doi.org/10.1007/s11894-023-00878-5>
20. Thomas-Dupont P., Velázquez-Soto H., Izaguirre-Hernández I.Y., et al. Obesity contributes to inflammation in patients with IBS via complement component 3 and C-reactive protein. *Nutrients*. 2022;14(24):5227.
DOI: <https://doi.org/10.3390/nu14245227>
21. Prevalence of overweight, obesity, and extreme obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018
[\[https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm\]](https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm) Retrieved June 3, 2025.
22. Pan X., Tan B., Chin Y.H., Cheng E., Lee Z, h Kong G., et al. Efficacy and safety of tirzepatide, GLP -1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. *Obesity*. 2024;32(5):840-856.
DOI: <https://doi.org/10.1002/oby.24002>
23. Collins L., Costello R.A. Glucagon-like peptide-1 receptor agonists. In *StatPearls*. Florida: StatPearls Publishing; 2024.
[\[http://www.ncbi.nlm.nih.gov/books/NBK551568/\]](http://www.ncbi.nlm.nih.gov/books/NBK551568/)
24. Aldhaleei W.A., Abegaz T.M., Bhagavathula A.S. Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health All of Us cohort. *Pharmaceuticals*. 2024;17(2):199. DOI: <https://doi.org/10.3390/ph17020199>
25. Wan J., Ferrari C., Tadros M. GLP-1RA Essentials in gastroenterology: side effect management, precautions for endoscopy and applications for gastrointestinal disease treatment. *Gastroenterol Insights*. 2024;15(1):191-212.
DOI: <https://doi.org/10.3390/gastroent15010014>

26. Gorgojo-Martínez, J.J.; Mezquita-Raya, P.; Carretero-Gómez, J.; Castro, A.; Cebrián-Cuenca, A.; de Torres-Sánchez, A. et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. *J Clin Med.* 2022;12(1):145.
DOI: <https://doi.org/10.3390/jcm12010145>
27. Chantler S., Griffiths A., Matu J., Davison G., Jones B., Deighton K. The effects of exercise on indirect markers of gut damage and permeability: a systematic review and meta-analysis. *Sports Med.* 2021;51(1):113-124.
DOI: <https://doi.org/10.1007/s40279-020-01348-y>
28. Ribeiro F.M., Petriz B., Marques G., Kamilla L.H., Franco O.L. Is there an exercise-intensity threshold capable of avoiding the leaky gut? *Front Nutr.* 2021; 8:627289.
DOI: <https://doi.org/10.3389/fnut.2021.627289>
29. Chantler S., Griffiths A., Matu J., Davison G., Holliday A., Jones B. A systematic review: role of dietary supplements on markers of exercise-associated gut damage and permeability. *Durkalec-Michalski K, ed. PLOS ONE.* 2022;17(4): e0266379.
DOI: <https://doi.org/10.1371/journal.pone.0266379>
30. Pimentel M., Lembo A., Chey W.D., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med.* 2011;364(1):22-32.
DOI: <https://doi.org/10.1056/NEJMoa1004409>
31. Camilleri M. Diagnosis and treatment of irritable bowel syndrome: A Review. *JAMA.* 2021;325(9):865.
DOI: <https://doi.org/10.1001/jama.2020.22532>
32. Nee J., Lembo A. Review article: current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). *Aliment Pharmacol Ther.* 2021;54(S1). DOI: <https://doi.org/10.1111/apt.16625>
33. Martirosyan D., Kanya H., Nadalet C. Can functional foods reduce the risk of disease? Advancement of functional food definition and steps to create functional food products. *Funct Foods Health Dis.* 2021;11(5):213.
DOI: <https://doi.org/10.31989/ffhd.v11i5.788>
34. Van Klinken B.J.W., Stewart M.L., Kalgaonkar S., Chae L. Health-promoting opportunities of hemp hull: the potential of bioactive compounds. *J Diet Suppl.* 2024;21(4):543-557.
DOI: <https://doi.org/10.1080/19390211.2024.2308264>
35. Bosman M., Elsenbruch S., Corsetti M., et al. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2021;6(6):459-473.
DOI: [https://doi.org/10.1016/S2468-1253\(21\)00023-6](https://doi.org/10.1016/S2468-1253(21)00023-6)